We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Estromineral Serena Plus and Symptomatic Menopause

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01730989
Recruitment Status : Unknown
Verified November 2012 by Rottapharm.
Recruitment status was:  Not yet recruiting
First Posted : November 21, 2012
Last Update Posted : November 21, 2012
Information provided by (Responsible Party):

Brief Summary:

Oestrogen hormone deficiency in menopause leads to symptoms of which hot flushes, night sweats, insomnia and mood changes are the most frequent and, ultimately, worsen the quality of life. The gradual decline of oestrogen from peri-menopause results in altered function of many neurotransmitters, such as dopamine, melatonin and neuropeptides including beta-endorphins, which modulate the function of the hypothalamus and are involved in body thermoregulation.

In post-menopause, dopaminergic activity is significantly reduced and stimulus of the D2 receptors is effective in relieving hot flushes and in reducing the accompanying psychological symptoms.

The use of hormone replacement therapy, which is generally prescribed in the case of moderate or severe symptoms, is limited due to real contraindications or simply the woman's refusal to take the therapy, despite the presence of symptoms requiring its use.

A food supplement, named Estromineral (E), based on natural ingredients such as isoflavones, the absorption of which is increased by the presence of Lactobacillus sporogenes, and Vitamin D3 and calcium, strengthening bone mineralization, has been found to be effective at reducing vasomotor symptoms.

To potentiate the effect of E on the most frequent symptoms in menopause, it was considered rational to add the extracts of magnolia, active on psycho-affective symptoms, and chaste tree, acting on both hot flushes and psychological symptoms and a new food supplement was developed: Estromineral Serena Plus (ESP).

Estromineral Serena Plus is an association of isoflavones with added Lactobacillus, chaste tree and magnolia, active on menopausal vasomotor symptoms and on psycho-affective symptoms.

Condition or disease Intervention/treatment
Menopause Dietary Supplement: Estromineral Serena Plus Dietary Supplement: Estromineral

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Controlled Clinical Study on the Activity of the Combination of Isoflavones, Agnocastus and Magnolia Extract in Menopause
Study Start Date : November 2012
Estimated Primary Completion Date : November 2013
Estimated Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Menopause
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Estromineral Serena Plus

Estromineral Serena Plus is an association of soy isoflavones, Lactobacillus sporogenes, magnolia, chaste tree, Vitamin D3, calcium and magnesium.

1 tablet oad for 12 weeks

Dietary Supplement: Estromineral Serena Plus
Active Comparator: Estromineral

Estromineral is an association of soy isoflavones, Lactobacillus sporogenes, Vitamin D3, and calcium.

1 tablet oad for 12 weeks

Dietary Supplement: Estromineral

Primary Outcome Measures :
  1. Kupperman index [ Time Frame: up to 12 weeks ]
    To calculate the Kupperman index, the symptoms were weighted as follows: hot flashes (4), insomnia (2), nervousness (2), and all other symptoms (night sweats, depressed mood (melancholy), dizziness, tiredness, joint and muscular pain, headache, and palpitations (1). The highest potential score is thus 51. The score of hot flashes was based on number of complaints per day: slight (more than 5), moderate (5-10), and severe (more than 10)

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: 4, 8 and 12 weeks ]
    Onset duration and severity of adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • female menopausal age
  • more than 5 hot flushes/day
  • mood or sleep changes

Exclusion Criteria:

  • hormone replacement therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01730989

Siena University Not yet recruiting
Siena, Italy, 53100
Principal Investigator: Vincenzo De Leo, MD         
Sponsors and Collaborators
Principal Investigator: Vincenzo De Leo, MD Siena University

Responsible Party: Rottapharm
ClinicalTrials.gov Identifier: NCT01730989     History of Changes
Other Study ID Numbers: ESP-CPR-0312
First Posted: November 21, 2012    Key Record Dates
Last Update Posted: November 21, 2012
Last Verified: November 2012

Keywords provided by Rottapharm:
hot flushes
chaste tree